| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
1998-05-29^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2001-02-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20010012995-A |
| titleOfInvention |
Therapeutic agent for erection failure |
| abstract |
Treatments for erectile dysfunction and female sexual dysfunction without problems occurring during oral administration and direct injection show a safe and excellent effect. For transmucosal administration, such as intranasal administration, transdermal administration or intranasal mucosal administration or penile mucosal administration, characterized in that it contains at least one compound having cyclic GMP phosphodiesterase inhibitory activity or a salt thereof as an active ingredient. Erectile dysfunction and sexual dysfunction in women. |
| priorityDate |
1997-05-29^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |